Scheme of Arrangement. Chandigarh Bench sanctioning the of Scheme of Arrangement for Amalgamation. on July 17, 2025 has approved the Scheme of Arrangement for Amalgamation of Ind-Swift Limited.
A merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
Prior statements by this company that CapitSignal has recorded changing.
In the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Looking ahead, on the domestic side we are focused on expanding our ethical footprint into peninsular India and into high-growth chronic therapeutic categories, targeting 15-20% CAGR growth in this business.
We expect FY27 to witness revenue growth of more than 50%.
FY30 is very long way to go, but yes, we would look for a revenue of minimum ₹1500 crores of a revenue and maybe a net profit of approx ₹200 plus.
We may revise this. We don't want to overproject and want to say that we'll do this one year in advance. But by the end of the financial year, we'll revisit all these numbers.
